JP2012519657A5 - - Google Patents

Download PDF

Info

Publication number
JP2012519657A5
JP2012519657A5 JP2011550669A JP2011550669A JP2012519657A5 JP 2012519657 A5 JP2012519657 A5 JP 2012519657A5 JP 2011550669 A JP2011550669 A JP 2011550669A JP 2011550669 A JP2011550669 A JP 2011550669A JP 2012519657 A5 JP2012519657 A5 JP 2012519657A5
Authority
JP
Japan
Prior art keywords
charged
composition
stabilizer
group
cyclic polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011550669A
Other languages
English (en)
Japanese (ja)
Other versions
JP5654498B2 (ja
JP2012519657A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/000502 external-priority patent/WO2010097700A1/en
Publication of JP2012519657A publication Critical patent/JP2012519657A/ja
Publication of JP2012519657A5 publication Critical patent/JP2012519657A5/ja
Application granted granted Critical
Publication of JP5654498B2 publication Critical patent/JP5654498B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011550669A 2009-02-25 2010-02-24 ベンダムスチン環状多糖組成物 Active JP5654498B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US20854109P 2009-02-25 2009-02-25
US61/208,541 2009-02-25
US26994409P 2009-07-01 2009-07-01
US61/269,944 2009-07-01
US27136409P 2009-07-20 2009-07-20
US61/271,364 2009-07-20
US27929309P 2009-10-19 2009-10-19
US61/279,293 2009-10-19
PCT/IB2010/000502 WO2010097700A1 (en) 2009-02-25 2010-02-24 Bendamustine cyclopolysaccharide compositions
US12/711,979 US8436032B2 (en) 2009-02-25 2010-02-24 Bendamustine cyclopolysaccharide compositions
US12/711,979 2010-02-24

Publications (3)

Publication Number Publication Date
JP2012519657A JP2012519657A (ja) 2012-08-30
JP2012519657A5 true JP2012519657A5 (OSRAM) 2012-11-22
JP5654498B2 JP5654498B2 (ja) 2015-01-14

Family

ID=42631521

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011550669A Active JP5654498B2 (ja) 2009-02-25 2010-02-24 ベンダムスチン環状多糖組成物

Country Status (12)

Country Link
US (2) US8436032B2 (OSRAM)
EP (2) EP2792369B1 (OSRAM)
JP (1) JP5654498B2 (OSRAM)
KR (1) KR101798951B1 (OSRAM)
CN (2) CN102935080A (OSRAM)
AU (1) AU2010217297A1 (OSRAM)
CA (1) CA2753641C (OSRAM)
ES (2) ES2525257T3 (OSRAM)
HU (1) HUE038234T2 (OSRAM)
NO (1) NO2792369T3 (OSRAM)
RU (2) RU2734236C2 (OSRAM)
WO (1) WO2010097700A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010217297A1 (en) 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
RS62327B1 (sr) 2010-01-28 2021-10-29 Eagle Pharmaceuticals Inc Formulacije bendamustina
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
JP2014526512A (ja) * 2011-09-18 2014-10-06 ユーロ−セルティーク エス．エイ． 医薬組成物
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
HRP20230276T1 (hr) 2012-03-20 2023-04-28 Eagle Pharmaceuticals, Inc. Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni
DK2827862T3 (da) 2012-03-20 2024-02-12 Eagle Pharmaceuticals Inc Formuleringer af bendamustin
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
EP2925327B1 (en) * 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
WO2015031198A2 (en) * 2013-08-27 2015-03-05 Voudouris Vasilios Bendamustine pharmaceutical compositions
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
US11266631B2 (en) 2016-10-11 2022-03-08 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
EP3691637A1 (en) * 2017-10-05 2020-08-12 TUBE Pharmaceuticals GmbH Oral bendamustine formulations
US11730815B2 (en) * 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
WO2020128912A1 (en) 2018-12-18 2020-06-25 Mundipharma International Corporation Limited Compounds for treating lymphoma or a t-cell malignant disease
US20220304983A1 (en) * 2020-04-09 2022-09-29 Bika Biotech (Guangzhou) Co., Ltd Bendamustine composition and use thereof
CN111557904A (zh) * 2020-04-09 2020-08-21 比卡生物科技（广州）有限公司 苯达莫司汀组合物及其用途
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5068226A (en) * 1987-12-07 1991-11-26 Cyclex, Inc. Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
DE59607089D1 (de) * 1995-03-10 2001-07-19 Roche Diagnostics Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
JP4979843B2 (ja) * 1995-03-10 2012-07-18 ロッシュ ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 微粒子の形のポリペプチド含有投薬形
US6624141B1 (en) * 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
EP1499361B1 (en) * 2002-04-19 2012-08-08 Novartis AG Novel biomaterials, their preparation and use
SG176314A1 (en) * 2002-12-31 2011-12-29 Altus Pharmaceuticals Inc Human growth hormone crystals and methods for preparing them
KR20070007075A (ko) * 2003-12-31 2007-01-12 사이덱스 인크 술포알킬 에테르 시클로덱스트린 및 코르티코스테로이드를함유한 흡입용 제형
EP1740184A1 (en) * 2004-03-30 2007-01-10 Pfizer Products Incorporated Combinations of signal transduction inhibitors
JP2008501720A (ja) * 2004-06-07 2008-01-24 ナステック ファーマスーティカル カンパニー インク． タンパク質又はポリペプチドである安定化剤不含インターフェロンベータの鼻腔内製剤
WO2006013084A1 (en) * 2004-08-03 2006-02-09 Royal College Of Surgeons In Ireland Phenytoin formulations, and uses thereof in wound healing
JP2008519032A (ja) * 2004-11-03 2008-06-05 キュラジェン コーポレイション Ｆｇｆ−２０の調合物、生成方法および使用
AU2005317047A1 (en) * 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
UA94036C2 (ru) * 2005-01-14 2011-04-11 Сефалон, Инк. Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP1848813B1 (en) 2005-01-28 2013-04-10 Brigham Young University Bacterial glycolipid activation of cd1d-restricted nkt cells
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN1846685A (zh) 2006-01-25 2006-10-18 济南帅华医药科技有限公司 含苯达莫司汀和其增效剂的缓释注射剂
US20100143481A1 (en) 2006-11-08 2010-06-10 Dinesh Shenoy Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
US8425459B2 (en) * 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
ES2373867T3 (es) 2007-03-02 2012-02-09 The University Of Wollongong Composiciones y procedimientos para el suministro de agentes anticancerosos.
CN101219113A (zh) 2008-01-28 2008-07-16 济南帅华医药科技有限公司 含苯达莫司汀的复方抗癌缓释注射剂
AU2010217297A1 (en) 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
CN101606934B (zh) 2009-07-27 2011-09-28 江苏奥赛康药业有限公司 盐酸苯达莫司汀组合物

Similar Documents

Publication Publication Date Title
JP2012519657A5 (OSRAM)
RU2011138844A (ru) Композиции бендамустина и циклополисахарида
Acar et al. Self-assembling peptide-based building blocks in medical applications
JP2015536356A5 (OSRAM)
EP3321367A3 (en) Vector
BR112015023168A2 (pt) composições de dicetopiperazina microcristalina e métodos
JP2019530462A5 (OSRAM)
JP2016538885A5 (OSRAM)
JP2015513897A5 (OSRAM)
JP2016222689A5 (ja) 合成ペプチド及び乾燥粉末薬剤輸送システム
Barros et al. A review of solute encapsulating nanoparticles used as delivery systems with emphasis on branched amphipathic peptide capsules
WO2015025217A3 (en) Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
BR112015002055A2 (pt) acetato succinato de hidroxialquil metil celulose, composição, dispersão sólida, processo para produzir uma dispersão sólida, forma de dosagem e cápsula de envoltório
IL227947A0 (en) Preparations containing antibodies that bind to the glycoprotein hemagglutinin a and the extracellular domain of the polypeptide to the transverse domain of matrix 2 (e2m) from influenza virus origin and their uses
WO2015048498A3 (en) Carrier-free biologically-active protein nanostructures
JP2014517694A5 (OSRAM)
WO2014145932A3 (en) Specific multivalent virus-like particle vaccines and uses thereof
JP2015533791A5 (OSRAM)
JP2014533756A5 (OSRAM)
JP2019531092A5 (OSRAM)
WO2008129971A1 (ja) 改良された持続感染型センダイウイルスベクター
JP2015506705A5 (OSRAM)
JP2011195814A5 (OSRAM)
WO2012082803A3 (en) Method for inducing an immune response against avian, swine, spanish, h1n1, h5n9 influenza viruses and formulations thereof
HK1216544A1 (zh) 病毒載體納米膠囊靶向基因治療及其製備